Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Radovic, Milan
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Completed	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	08/24	09/24
NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)	Terminated	2	19	Europe, US, RoW	Daxdilimab, Placebo (Normal Saline)	Amgen, Horizon Therapeutics Ireland DAC	Lupus Nephritis	01/24	01/24
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis	Suspended	2	279	Europe, US, RoW	zetomipzomib, KZR-616, placebo, matching placebo	Kezar Life Sciences, Inc.	Lupus Nephritis	05/26	07/26
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Active, not recruiting	1	16	Europe, Japan, US, RoW	Mezagitamab, TAK-079	Takeda	Kidney Disease, Glomerulonephritis	03/26	03/26
Ordenidze, Inga
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Completed	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	08/24	09/24